When I was diagnosed with Parkinson’s in August 2019, a doctor told me that Sinemet (Levodopa/Carbidopa), the starter drug of ...

The origin of many diseases such as Alzheimer's or Parkinson's can be found at the molecular level in our body, in other ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Researchers have identified a potential biomarker of Parkinson's disease progression. According to the new study, patients with a slow progression of the pathology would have a significant increase in ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Early initiation of pimavanserin among patients with Parkinson disease psychosis were more likely to experience complete symptom resolution.